Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives $11.00 Consensus Target Price from Analysts

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) have been assigned an average recommendation of “Buy” from the seven brokerages that are presently covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $11.00.

AQST has been the subject of several recent research reports. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a report on Friday, December 20th. Cantor Fitzgerald assumed coverage on Aquestive Therapeutics in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 target price for the company. Finally, Leerink Partners boosted their price target on Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th.

Institutional Investors Weigh In On Aquestive Therapeutics

A number of hedge funds have recently bought and sold shares of AQST. nVerses Capital LLC acquired a new stake in shares of Aquestive Therapeutics during the third quarter worth approximately $28,000. New York State Common Retirement Fund boosted its stake in Aquestive Therapeutics by 713.3% during the 4th quarter. New York State Common Retirement Fund now owns 12,200 shares of the company’s stock valued at $43,000 after acquiring an additional 10,700 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Aquestive Therapeutics during the 4th quarter worth $44,000. PKS Advisory Services LLC bought a new stake in shares of Aquestive Therapeutics in the 4th quarter worth about $63,000. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in shares of Aquestive Therapeutics in the 4th quarter valued at about $69,000. Institutional investors and hedge funds own 32.45% of the company’s stock.

Aquestive Therapeutics Stock Down 4.3 %

AQST opened at $3.32 on Friday. The company has a 50 day moving average of $3.33 and a two-hundred day moving average of $4.19. Aquestive Therapeutics has a 52-week low of $2.24 and a 52-week high of $6.23. The company has a market cap of $302.72 million, a P/E ratio of -7.38 and a beta of 2.67.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.